Lawmakers Press FDA on Getting ALS Therapies to Patients
Home lawmakers entreated the FDA to be more flexible in reviewing capacity therapies for amyotrophic lateral sclerosis (ALS), and various neurodegenerative ailments, at some stage in a hearing of the Home Vitality & Commerce Health Subcommittee on Thursday. Participants also…